These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2260141)

  • 21. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.
    Gresele P; Deckmyn H; Arnout J; Lemmens J; Janssens W; Vermylen J
    Lancet; 1984 May; 1(8384):991-4. PubMed ID: 6143969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug.
    Stegmeier K; Pill J; Müller-Beckmann B; Schmidt FH; Witte EC; Wolff HP; Patscheke H
    Thromb Res; 1984 Aug; 35(4):379-95. PubMed ID: 6385334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate against 9,11-dideoxy- 9 alpha, 11 alpha-epoxymethano-prostaglandin F2 alpha-induced sudden death in guinea-pigs and rats.
    Shirakura S; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1242-5. PubMed ID: 1815523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BAY u3405 is a potent and competitive antagonist of U46619, PGD2 and 9 alpha, 11 beta PGF2 alpha-induced contractions of airway smooth muscle.
    Norman P; Cuthbert NJ; Gardiner PJ; McKenniff MG
    Ann N Y Acad Sci; 1991; 629():396-8. PubMed ID: 1952564
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of cyclooxygenase metabolites in mediating platelet-induced baroreceptor dysfunction.
    Li Z; Su X; Chapleau MW
    Am J Physiol; 1995 Aug; 269(2 Pt 2):H599-608. PubMed ID: 7653624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thromboxane A2 analogue, U-46619, potentiates calcium-activated force in human umbilical artery.
    Crichton CA; Templeton AG; McGrath JC; Smith GL
    Am J Physiol; 1993 Jun; 264(6 Pt 2):H1878-83. PubMed ID: 8322917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Thrombocyte interaction with a collagen substrate: the role of thrombocyte-synthesized prostaglandin endoperoxides and thromboxane A2].
    Mazurov AB; Leĭtin VL; Repin VS
    Biull Eksp Biol Med; 1984 Nov; 98(11):563-6. PubMed ID: 6439262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of ADP secretion and thromboxane synthesis in factor VIII binding to platelets.
    Di Minno G; Shapiro SS; Catalano PM; De Marco L; Murphy S
    Blood; 1983 Jul; 62(1):186-90. PubMed ID: 6407547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations.
    Norel X; Labat C; Gardiner PJ; Brink C
    Br J Pharmacol; 1991 Nov; 104(3):591-5. PubMed ID: 1797322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tripeptide ZAMI-420 inhibits thromboxane-induced gastric vasoconstriction and ischaemia.
    Moroni D; Gervasi GB; Patella P; Visentin L; Maselli MA; Bergamaschi M
    Int J Tissue React; 1983; 5(3):249-52. PubMed ID: 6654624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of thromboxanes in gastrointestinal physiopathology.
    Bennett TA
    Int J Tissue React; 1983; 5(3):237-9. PubMed ID: 6686219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary vascular responses to thromboxane A2 as unmasked by OKY-1581. A novel inhibitor of thromboxane synthesis.
    Kadowitz PJ; Nandiwada PA; Spannhake EW; Rosenson RS; McNamara DB; Hyman AL
    Chest; 1983 May; 83(5 Suppl):72S-74S. PubMed ID: 6404609
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: potentiation of antiplatelet effects of aspirin.
    Escolar G; Albors M; Garrido M; Bioque G; Díaz Ricart M; Carretero M; Ordinas A
    Eur J Clin Invest; 1998 Jul; 28(7):562-8. PubMed ID: 9726037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostacyclin and cerebral vessel relaxation.
    Paul KS; Whalley ET; Forster C; Lye R; Dutton J
    J Neurosurg; 1982 Sep; 57(3):334-40. PubMed ID: 7047688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
    Bitterman H; Yanagisawa A; Lefer AM
    Circ Shock; 1986; 20(1):1-11. PubMed ID: 2945667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
    Block HU; Förster W; Heinroth I
    Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre- and postjunctional effects of a thromboxane mimetic in canine bronchi.
    Janssen LJ; Daniel EE
    Am J Physiol; 1991 Oct; 261(4 Pt 1):L271-6. PubMed ID: 1928361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of naftidrofuryl on platelet-induced vasospasm in vitro. Role of antiserotonergic actions.
    Verheggen R; Schrör K
    Arzneimittelforschung; 1993 Mar; 43(3):330-4. PubMed ID: 8489562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different sensitivity of basilar and saphenous arteries to thromboxane A2-induced contractions. Effect of imidazole 2-hydroxybenzoate (ITF 182).
    Pagella PG; Agozzino S; Bellavite O; Donà GC; Mendola N
    Arzneimittelforschung; 1984; 34(11):1514-6. PubMed ID: 6596952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between platelet-released serotonin and thromboxane A2 on human digital arteries.
    Young MS; Iwanov V; Moulds RF
    Clin Exp Pharmacol Physiol; 1986 Feb; 13(2):143-52. PubMed ID: 3708917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.